Form 4: Heron Therapeutics Executive Ira Duarte Reports Stock Transactions

EVP and Chief Financial Officer of Heron Therapeutics, Ira Duarte, reports the acquisition of 3,874 shares of common stock and 3,874 restricted stock units on January 19, 2025.

Summary

• Ira Duarte, the EVP and Chief Financial Officer of Heron Therapeutics, reported a transaction on January 19, 2025.
• The transaction involved the acquisition of 3,874 shares of common stock.
• Additionally, 3,874 restricted stock units were acquired, each representing a contingent right to receive one share of common stock.
• Following these transactions, Mr. Duarte beneficially owns 120,580 shares of common stock and 46,492 restricted stock units.
• The restricted stock units vest in 16 equal quarterly installments starting one quarter after the grant date of January 19, 2024.

Sentiment

Score: 6

Explanation: The document reflects routine executive stock transactions, which are neither particularly positive nor negative. It is a neutral event.

Positives

• The acquisition of shares and restricted stock units by a key executive could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine filing related to executive compensation and stock ownership, which is common in the pharmaceutical industry.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the pharmaceutical industry to align executive interests with shareholder value.
• The vesting schedule of the restricted stock units is typical for executive compensation packages.
• Similar filings are regularly made by executives at comparable companies such as Amgen, Gilead Sciences, and Regeneron.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates executive confidence in the company.

Key Dates

Keywords

Heron Therapeutics, Ira Duarte, stock transaction, restricted stock units, Form 4, insider trading, executive compensation